Author(s): Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A, , Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A, , Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A, , Fujimura T, Yonekura S, Horiguchi S, Taniguchi Y, Saito A,
Abstract Share this page
Abstract The aims of this study were to examine the therapeutic effects of sublingual immunotherapy (SLIT) and to identify potential biomarkers that would predict the therapeutic response in a randomized, double-blind, placebo-controlled clinical trial. The trial was carried out over two pollinosis seasons in 2007 and 2008. Carry-over therapeutic effects were analyzed in 2009. SLIT significantly ameliorated the symptoms of pollinosis during the 2008 and 2009 pollen seasons. Cry j 1-specific cytokine production in a subgroup of patients with mild disease in the SLIT group was significantly attenuated. The ratio of specific IgE to total IgE before treatment correlated with the symptom-medication score in the SLIT group in 2008. Patients with increased Cry j 1-iTreg in the SLIT group had significantly improved QOL and QOL-symptom scores. In summary, the specific IgE to total IgE ratio and upregulation of Cry j 1-iTreg are candidates for biomarker of the clinical response to SLIT. Copyright © 2011 Elsevier Inc. All rights reserved.
This article was published in Clin Immunol
and referenced in Immunotherapy: Open Access